These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27531894)

  • 1. Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.
    Shouse G; de Necochea-Campion R; Mirshahidi S; Liu X; Chen CS
    Oncotarget; 2016 Sep; 7(38):61081-61092. PubMed ID: 27531894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.
    Ruvolo PP; Qui YH; Coombes KR; Zhang N; Ruvolo VR; Borthakur G; Konopleva M; Andreeff M; Kornblau SM
    Leukemia; 2011 Nov; 25(11):1711-7. PubMed ID: 21660042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.
    Ruvolo PP; Ruvolo VR; Jacamo R; Burks JK; Zeng Z; Duvvuri SR; Zhou L; Qiu Y; Coombes KR; Zhang N; Yoo SY; Pan R; Hail N; Konopleva M; Calin G; Kornblau SM; Andreeff M
    Biochim Biophys Acta; 2014 Sep; 1843(9):1969-77. PubMed ID: 24858343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt.
    Kuo YC; Huang KY; Yang CH; Yang YS; Lee WY; Chiang CW
    J Biol Chem; 2008 Jan; 283(4):1882-92. PubMed ID: 18042541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
    Smith AM; Dun MD; Lee EM; Harrison C; Kahl R; Flanagan H; Panicker N; Mashkani B; Don AS; Morris J; Toop H; Lock RB; Powell JA; Thomas D; Guthridge MA; Moore A; Ashman LK; Skelding KA; Enjeti A; Verrills NM
    Oncotarget; 2016 Jul; 7(30):47465-47478. PubMed ID: 27329844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
    Yang Y; Huang Q; Lu Y; Li X; Huang S
    J Cell Biochem; 2012 Apr; 113(4):1314-22. PubMed ID: 22109829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.
    Roberts KG; Smith AM; McDougall F; Carpenter H; Horan M; Neviani P; Powell JA; Thomas D; Guthridge MA; Perrotti D; Sim AT; Ashman LK; Verrills NM
    Cancer Res; 2010 Jul; 70(13):5438-47. PubMed ID: 20551067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The B55α regulatory subunit of protein phosphatase 2A mediates fibroblast growth factor-induced p107 dephosphorylation and growth arrest in chondrocytes.
    Kolupaeva V; Daempfling L; Basilico C
    Mol Cell Biol; 2013 Aug; 33(15):2865-78. PubMed ID: 23716589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PP2A B55α inhibits epithelial-mesenchymal transition via regulation of Slug expression in non-small cell lung cancer.
    Singh D; Qiu Z; Jonathan SM; Fa P; Thomas H; Prasad CB; Cai S; Wang JJ; Yan C; Zhang X; Venere M; Li Z; Sizemore ST; Wang QE; Zhang J
    Cancer Lett; 2024 Aug; 598():217110. PubMed ID: 38986733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
    Cristóbal I; Garcia-Orti L; Cirauqui C; Alonso MM; Calasanz MJ; Odero MD
    Leukemia; 2011 Apr; 25(4):606-14. PubMed ID: 21233840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells.
    Hales EC; Orr SM; Larson Gedman A; Taub JW; Matherly LH
    J Biol Chem; 2013 Aug; 288(31):22836-48. PubMed ID: 23788636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.
    Vicente C; Arriazu E; Martínez-Balsalobre E; Peris I; Marcotegui N; García-Ramírez P; Pippa R; Rabal O; Oyarzábal J; Guruceaga E; Prósper F; Mateos MC; Cayuela ML; Odero MD
    Cancer Lett; 2020 Jan; 468():1-13. PubMed ID: 31593801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.
    Chen L; Luo LF; Lu J; Li L; Liu YF; Wang J; Liu H; Song H; Jiang H; Chen SJ; Luo C; Li KK
    PLoS One; 2014; 9(7):e103033. PubMed ID: 25050888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B55α/PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling: A Complementary Approach To Disrupt Pathological Vessels?
    Ehling M; Celus W; Martín-Pérez R; Alba-Rovira R; Willox S; Ponti D; Cid MC; Jones EAV; Di Conza G; Mazzone M
    Circ Res; 2020 Aug; 127(6):707-723. PubMed ID: 32527198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical characterization of the Eya and PP2A-B55α interaction.
    Alderman C; Anderson R; Zhang L; Hughes CJ; Li X; Ebmeier C; Wagley ME; Ahn NG; Ford HL; Zhao R
    J Biol Chem; 2024 Jul; 300(7):107408. PubMed ID: 38796066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
    Di Mambro A; Arroyo-Berdugo Y; Fioretti T; Randles M; Cozzuto L; Rajeeve V; Cevenini A; Austin MJ; Esposito G; Ponomarenko J; Lucas CM; Cutillas P; Gribben J; Williams O; Calle Y; Patel B; Esposito MT
    Oncogene; 2023 Dec; 42(50):3670-3683. PubMed ID: 37891368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of Novel FTY720 Analogs with Anticancer Activity through PP2A Activation.
    Shrestha J; Ki SH; Shin SM; Kim SW; Lee JY; Jun HS; Lee T; Kim S; Baek DJ; Park EY
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30355990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of Yin Yang 1 enhances anticancer effects of cisplatin through protein phosphatase 2A-mediated T308 dephosphorylation of AKT.
    Zhao L; Li R; Gan YH
    Cell Death Dis; 2018 Jul; 9(7):747. PubMed ID: 29970878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Akt-dependent Pp2a activity is required for epidermal barrier formation during late embryonic development.
    O'Shaughnessy RF; Welti JC; Sully K; Byrne C
    Development; 2009 Oct; 136(20):3423-31. PubMed ID: 19762425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of PP2A activator on proliferation of HL-60 cells and analysis of PP2A activity changes in patients with acute myeloid leukemia].
    Yang Y; Li XQ; Huang Q; Huang SA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):594-7. PubMed ID: 21729530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.